Ewing, New Jersey-based Church & Dwight Co., Inc. (CHD) develops, manufactures, and markets household, personal care, and ...

Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart and ...

Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally. Hypercholesterolemia is one of the major risk factors for CHD. With the increase in aging populations and ...

Church & Dwight Co Inc (NYSE:CHD) reported fourth-quarter sales growth of 3.5% year-on-year to $1.58 billion, beating the analyst consensus estimate of $1.56 billion. Organic sales increased 4.2% ...

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

while ECLIPSE 3, the head-to-head trial, will evaluate the combination with bulevirtide in treatment-naïve individuals. CHD is said to occur due to the hepatitis delta virus (HDV), leading to ...